Newswire & Press Release / Transgene and NEC Present First Clinical Benefits of Neoantigen Cancer Vaccine, TG4050 - Pharma / BioTech / Nutrition - NEC Corporation newswiretoday.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from newswiretoday.com Daily Mail and Mail on Sunday newspapers.
Extensive Phase I immunology data confirm strong immunogenicity of TG4050 in the adjuvant treatment of head and neck cancers. All treated patients remain disease-free after a median follow-up of.